ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1974

The Impact of Concomitant Shoulder Osteoarthritis in Polymyalgia Rheumatica

Patricia Harkins1, Sharon Cowley2, Robert Harrington3, David Kane4 and Richard Conway5, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3St. James's Hospital, Dublin, Dublin, Ireland, 4Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 5Trinity College Dublin, Dublin, Ireland

Meeting: ACR Convergence 2024

Keywords: Osteoarthritis, Patient reported outcomes, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease of the shoulder and pelvic girdle. In the majority of centres, baseline shoulder radiograph forms part of the initial diagnostic workup. However, the prevalence of concomitant osteoarthritis (OA), and indeed its impact on disease and patient reported outcomes remains unknown.

Methods: 43 consecutive patients, fulfilling the provisional 2012 EULAR/ACR PMR classification criteria were recruited via a fast track PMR clinic. At the initial clinic visit, patients underwent a bilateral shoulder radiograph, and patient reported outcomes including fatigue using the Functional Assessment of Chronic Illness Therapy – Fatigue scale (FACIT-F), mood  using the Patient Health Questionnaire(PHQ-9), anxiety using the Generalised Anxiety Disorder Assessment (GAD-7), pain (visual analogue scale (VAS)), and overall health related quality of life and disability using the Health Assessment Questionnaire-Disability Index(HAQ-DI) were collected. Normally distributed continuous variables are expressed as means with standard deviations (SD). Continuous variables are compared using the independent t-test. Categorical variables are summarised by frequency and percentage (%) and compared using the chi-square test or Fishers exact test. The association between continuous variables and categorical variables are assessed using the Kruskal-Wallis test.  The statistical analysis was performed using STATA MP Version 18. P values < 0.05 are considered statistically significant.

Results: A total of 43 patients, including 21 (48.8%) females, were recruited. 29 (67.4%) patients had evidence of degenerative change of their acromioclavicular joints on shoulder radiograph. Notably, no patient had evidence of erosive change, or crystal arthropathy. The mean age in those with degenerative changes was 70.21 (SD 7.87), and 73.29 (SD 7.17) in those without.

There was a statistically significant higher pVAS  (p=0.0049) and HAQ pain score (p=0.0041) in those with degenerative changes. There was also a statistically significant lower FACIT-F score in those with evidence of degenerative change (p=0.0376). There was no statistically significant difference between HAQ-DI or HAQ- global patient scores between the groups. Notably, the frequency of disease relapse at one year was higher in those with degenerative change (62%) versus those without (42.8%).

Conclusion: This study, demonstrates the high prevalence of concomitant acromioclavicular joint OA in those with PMR, and for the first time highlights the impact that this has on patient reported pain and fatigue, and overall disease outcomes. This has potential implications for PMR disease management, and it is intended that this study will bring increased awareness to the importance of screening for and addressing OA management where present in those with PMR.


Disclosures: P. Harkins: Janssen Pharmaceuticals, 5, Novartis Pharmaceuticals, 5; S. Cowley: AbbVie/Abbott, 12, Support to attend conference, Novartis, 5, 12, Support to attend conference; R. Harrington: None; D. Kane: None; R. Conway: AbbVie/Abbott, 5, 6, Celltrion, 5, Fresenius Kabi, 6, Galapagos, 6, Janssen, 5, 6, Novartis, 5, 6, UCB, 6, Viatris, 6.

To cite this abstract in AMA style:

Harkins P, Cowley S, Harrington R, Kane D, Conway R. The Impact of Concomitant Shoulder Osteoarthritis in Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-concomitant-shoulder-osteoarthritis-in-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-concomitant-shoulder-osteoarthritis-in-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology